Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pollution-Curbing Policies Possible Following Improved Air Quality During Beijing Olympics
The air in Beijing during the 2008 Olympics was cleaner than the previous year"s, due to aggressive efforts by the Chinese government to curtail traffic, increase emissions standards and halt construction in preparation for the games, according to a Cornell study.
generic viagra online
Blood-Pressure Drug Shrinks Scars In The Livers Hepatitis C Sufferers
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.
News of the day
People Sometimes Seek The Truth, But Most Prefer Like-Minded Views
We swim in a sea of information, but filter out most of what we see or hear. New analysis of data from dozens of studies sheds new light on how we choose what we do and do not hear. The study found that while people tend to avoid information that contradicts what they already think or believe, certain factors can cause them to seek out, or at least consider, other points of view.
Health Insurance

Presidio Pharmaceuticals, Inc. Selects PPI-461 As A Clinical Candidate In Their Hepatitis C Virus NS5A Program

Presidio Pharmaceuticals, Inc. announced that they have selected one of the lead compounds in their hepatitis C virus (HCV) NS5A program to advance toward clinical development. Inhibitors of the HCV NS5A protein are novel and distinct from those currently being pursued by others against the two enzymatic targets of HCV, protease or replicase. With response rates of approximately 50% and tolerance issues associated with standard of care treatments involving the combination of pegylated IFN and ribavirin, there is a clear need for potent, small molecule inhibitors that target multiple viral targets and can be administered orally in future combination therapies. The selected Presidio NS5A inhibitor, PPI-461, exhibits potent and selective activity against all HCV genotypes and showed good oral bioavailability and was well tolerated in animal studies, with elevated liver concentrations relative to serum levels, and potential for once daily dosing in humans. Resistance studies to date suggest that the compound will likely have a high resistance barrier requiring multiple substitutions within the NS5A gene. IND-enabling studies for PPI-461 are currently underway and the Company expects to commence clinical studies in 2010. Additional preclinical research continues on other distinct classes of compounds in the Company"s NS5A program. Presidio Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009